Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FDC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01216397
What this trial is testing

Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers

Who this might be right for
Healthy
Boehringer Ingelheim 40
Large-scale testing (Phase 3)Not Yet RecruitingNCT07619118
What this trial is testing

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

Who this might be right for
Hypercholesterolaemia
AstraZeneca 200
Testing effectiveness (Phase 2)Study completedNCT05134948
What this trial is testing

Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 24
Early research (Phase 1)Study completedNCT00552708
What this trial is testing

A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.

Who this might be right for
Hypertension
GlaxoSmithKline 55
Post-approval studies (Phase 4)Not Yet RecruitingNCT07459543
What this trial is testing

Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India

Who this might be right for
Unresectable MelanomaMetastatic Melanoma
Bristol-Myers Squibb 40
Early research (Phase 1)Looking for participantsNCT06733675
What this trial is testing

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Who this might be right for
Healthy VolunteerPharmacokineticsSafety+2 more
Basilea Pharmaceutica 96
Early research (Phase 1)Study completedNCT01540487
What this trial is testing

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

Who this might be right for
Healthy
Boehringer Ingelheim 48
Large-scale testing (Phase 3)WithdrawnNCT04129320
What this trial is testing

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Head and Neck CancerSquamous Cell Carcinoma of Head and Neck
MacroGenics
Early research (Phase 1)Study completedNCT01454622
What this trial is testing

Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

Who this might be right for
Healthy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 64
Early research (Phase 1)Study completedNCT05663073
What this trial is testing

Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers

Who this might be right for
Healthy Volunteers
Handok Inc. 46
Early research (Phase 1)Study completedNCT05118516
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects

Who this might be right for
Healthy Volunteer
Gannex Pharma Co., Ltd. 8
Early research (Phase 1)Study completedNCT02888054
What this trial is testing

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

Who this might be right for
Healthy
Ardea Biosciences, Inc. 28
Early research (Phase 1)Study completedNCT02658981
What this trial is testing

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Who this might be right for
GlioblastomaGliosarcomaRecurrent Brain Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Not applicableLooking for participantsNCT07420907
What this trial is testing

Study of the Progression of Chronic Cardiovascular Conditions

Who this might be right for
Cardiovascular Disease (CVD)Heart FailureAortic Stenosis+9 more
Prolaio 5,000
Large-scale testing (Phase 3)Study completedNCT02123654
What this trial is testing

UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

Who this might be right for
Hepatitis C Virus Infection
Bristol-Myers Squibb 297
Early research (Phase 1)Study completedNCT02195349
What this trial is testing

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis

Who this might be right for
Psoriasis
GlaxoSmithKline 67
Testing effectiveness (Phase 2)Study completedNCT06036836
What this trial is testing

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Who this might be right for
Solid TumorCutaneous Squamous Cell CarcinomaEndometrial Cancer
Merck Sharp & Dohme LLC 163
Early research (Phase 1)Study completedNCT02010944
What this trial is testing

Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Who this might be right for
Phase 1BioavailabilityHealthy Subjects
Astellas Pharma Europe B.V. 72
Testing effectiveness (Phase 2)Study completedNCT03743766
What this trial is testing

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Who this might be right for
Melanoma
John Kirkwood 43
Next Page